Jonathan O. Cole, M.D.—No competing interests to disclose.

Charles DeBattista, D.M.H., M.D.—Grant support: Abbott, AstraZeneca, Cephalon, CNS Response, Corcept, Cyberonics, Eli Lilly, GlaxoSmithKline, NARSAD, National Institute of Mental Health, Neuronetics, Novartis, Pfizer, Pritzker Foundation, Wyeth; Speaker/Consultant: Bristol-Myers Squibb, Cephalon, Corcept, Cyberonics, Eli Lilly, GlaxoSmithKline, Pfizer, Wyeth; Stock: Corcept.

Alan F. Schatzberg, M.D.—Consultant: Abbott, BrainCells, Bristol-Myers Squibb, Corcept, Eli Lilly, Forest, GlaxoSmithKline, Merck, Neuronetics, Novartis, Pathway Diagnostics, Pfizer, Quintiles, Wyeth; Equity: BrainCells, CeNeRx, Corcept (co-founder), Forest, Merck, Neurocrine, Pfizer, PharmaNeuroBoost, Somaxon; Intellectual property: Named inventor on pharmacogenetic use patents on prediction of antidepressant response and on glucocorticoid antagonists in psychotic major depression.